Health Affairs, 24, no. 1 (2005): 67-78
doi: 10.1377/hlthaff.24.1.67
© 2005 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (30)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Fleming, T. R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Fleming, T. R.
Related Collections
* Health Reform
* Physicians
* Quality Of Care
* Research And Technology
* Politics
* Evidence-Based Medicine

Case Studies

Surrogate Endpoints And FDA’s Accelerated Approval Process

Thomas R. Fleming

There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential "surrogates" for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention’s safety and efficacy.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc., January 1, 2010; 21(1): 7 - 12.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. R. Fleming, M. D. Rothmann, and H. L. Lu
Issues in Using Progression-Free Survival When Evaluating Oncology Products
J. Clin. Oncol., June 10, 2009; 27(17): 2874 - 2880.
[Abstract] [Full Text] [PDF]


Home page
Stat Methods Med ResHome page
P. Piedbois and J. Miller Croswell
Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective
Statistical Methods in Medical Research, October 1, 2008; 17(5): 519 - 527.
[Abstract] [PDF]


Home page
Mult SclerHome page
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778.
[Abstract] [PDF]


Home page
Stat Methods Med ResHome page
M. N Lassere
The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints
Statistical Methods in Medical Research, June 1, 2008; 17(3): 303 - 340.
[Abstract] [PDF]


Home page
Clin TrialsHome page
T. R Fleming, K. Sharples, J. McCall, A. Moore, A. Rodgers, and R. Stewart
Maintaining confidentiality of interim data to enhance trial integrity and credibility
Clinical Trials, April 1, 2008; 5(2): 157 - 167.
[Abstract] [PDF]


Home page
The OncologistHome page
C. C. Jaffe
Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design
Oncologist, April 1, 2008; 13(suppl_2): 14 - 18.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. Pazdur
Endpoints for Assessing Drug Activity in Clinical Trials
Oncologist, April 1, 2008; 13(suppl_2): 19 - 21.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al.
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
E. P. Rock, J. A. Scott, D. L. Kennedy, R. Sridhara, R. Pazdur, and L. B. Burke
Challenges to Use of Health-Related Quality of Life for Food and Drug Administration Approval of Anticancer Products
J Natl Cancer Inst Monographs, October 1, 2007; 2007(37): 27 - 30.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
N. Mayer-Hamblett, B. W. Ramsey, and R. A. Kronmal
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Proceedings of the ATS, August 1, 2007; 4(4): 370 - 377.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. P. Schuster
The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease
Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 224 - 230.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. G. Sorensen
Magnetic Resonance As a Cancer Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3274 - 3281.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
P. J. Neumann
Emerging Lessons From The Drug Effectiveness Review Project
Health Aff., July 1, 2006; 25(4): W262 - W271.
[Abstract] [Full Text] [PDF]


Home page
Ann Fam MedHome page
B. Starfield
Threads and Yarns: Weaving the Tapestry of Comorbidity
Ann. Fam. Med, March 1, 2006; 4(2): 101 - 103.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
A. Tefferi
Iron Chelation Therapy for Myelodysplastic Syndrome: If and When
Mayo Clin. Proc., February 1, 2006; 81(2): 197 - 198.
[Full Text] [PDF]


Home page
Eur Respir JHome page
W. C. Johnson and G. Raghu
Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures
Eur. Respir. J., November 1, 2005; 26(5): 755 - 758.
[Full Text] [PDF]


Home page
JCOHome page
T. R. Fleming
Objective Response Rate As a Surrogate End Point: A Commentary
J. Clin. Oncol., August 1, 2005; 23(22): 4845 - 4846.
[Full Text] [PDF]